Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Isis Pharmaceuticals will work with Janssen Biotech, part of Johnson & Johnson, to develop RNA-targeted drugs against autoimmune disorders of the gastrointestinal tract. Janssen has expertise in formulating drugs that can be delivered to targets in the gut. J&J will pay Isis $35 million up front. The agreement covers three programs for which Isis could receive another $800 million in license fees and milestone payments. If Janssen licenses promising drug candidates, it will handle the development, regulatory, and commercialization aspects.
This article has been sent to the following recipient: